BACKGROUND: Reported reasons for change or discontinuation of antiretroviral therapy ([delta]ART) include adverse events, intolerability, and nonadherence. Little is known how reasons for [delta]ART differ by gender. METHODS: In a retrospective cohort study, rates and reasons for [delta]ART alterations in a large University-based HIV clinic cohort were evaluated. Logistic regression analyses were used to evaluate the relationship between reasons for [delta]ART and gender. Cox proportional hazard models were used to investigate time to [delta]ART. RESULTS: In total, 631 HIV-positive individuals were analyzed. Women (n = 164) and men (n = 467) were equally likely (53.0% and 54.4%, respectively) to discontinue treatment within 12 month of initiating a new regimen. Reasons for [delta]ART, however, were different based on gender--women were more likely to [delta]ART due to poor adherence [adjusted odds ratio (OR), 1.44; 95% confidence interval (CI): 0.85 to 2.42], dermatologic symptoms (adjusted OR, 2.88; 95% CI: 1.01 to 8.18), neurological reasons (adjusted OR, 1.82; 95% CI: 0.98 to 3.39), constitutional symptoms (adjusted OR, 2.23; 95% CI: 1.10 to 4.51), and concurrent medical conditions (adjusted OR, 2.03; 95% CI: 1.00 to 4.12). CONCLUSIONS: Although the rates of [delta]ART are similar among men and women in clinical practice, the reasons for treatment changes are different based on gender. The potential for unique patterns of adverse events and poor adherence among women requires further investigation.
BACKGROUND: Reported reasons for change or discontinuation of antiretroviral therapy ([delta]ART) include adverse events, intolerability, and nonadherence. Little is known how reasons for [delta]ART differ by gender. METHODS: In a retrospective cohort study, rates and reasons for [delta]ART alterations in a large University-based HIV clinic cohort were evaluated. Logistic regression analyses were used to evaluate the relationship between reasons for [delta]ART and gender. Cox proportional hazard models were used to investigate time to [delta]ART. RESULTS: In total, 631 HIV-positive individuals were analyzed. Women (n = 164) and men (n = 467) were equally likely (53.0% and 54.4%, respectively) to discontinue treatment within 12 month of initiating a new regimen. Reasons for [delta]ART, however, were different based on gender--women were more likely to [delta]ART due to poor adherence [adjusted odds ratio (OR), 1.44; 95% confidence interval (CI): 0.85 to 2.42], dermatologic symptoms (adjusted OR, 2.88; 95% CI: 1.01 to 8.18), neurological reasons (adjusted OR, 1.82; 95% CI: 0.98 to 3.39), constitutional symptoms (adjusted OR, 2.23; 95% CI: 1.10 to 4.51), and concurrent medical conditions (adjusted OR, 2.03; 95% CI: 1.00 to 4.12). CONCLUSIONS: Although the rates of [delta]ART are similar among men and women in clinical practice, the reasons for treatment changes are different based on gender. The potential for unique patterns of adverse events and poor adherence among women requires further investigation.
Authors: Bruce R Schackman; Heather J Ribaudo; Amy Krambrink; Valery Hughes; Daniel R Kuritzkes; Roy M Gulick Journal: J Acquir Immune Defic Syndr Date: 2007-12-15 Impact factor: 3.731
Authors: Clare L Booth; Ana M Garcia-Diaz; Michael S Youle; Margaret A Johnson; Andrew Phillips; Anna Maria Geretti Journal: J Antimicrob Chemother Date: 2007-01-09 Impact factor: 5.790
Authors: Linda Ahdieh-Grant; Patrick M Tarwater; Michael F Schneider; Kathryn Anastos; Mardge Cohen; Ann Khalsa; Howard Minkoff; Mary Young; Ruth M Greenblatt Journal: J Acquir Immune Defic Syndr Date: 2005-04-01 Impact factor: 3.731
Authors: J S Currier; C Spino; J Grimes; C B Wofsy; D A Katzenstein; M D Hughes; S M Hammer; D J Cotton Journal: J Acquir Immune Defic Syndr Date: 2000-08-01 Impact factor: 3.731
Authors: M Oette; R Kaiser; M Däumer; G Fätkenheuer; J K Rockstroh; H Knechten; D Mitrenga; N Beerenwinkel; A Sagir; H Pfister; D Häussinger Journal: Dtsch Med Wochenschr Date: 2007-05-04 Impact factor: 0.628
Authors: Inge B Corless; Alex J Hoyt; Lynda Tyer-Viola; Elizabeth Sefcik; Jeanne Kemppainen; William L Holzemer; Lucille Sanzero Eller; Kathleen Nokes; J Craig Phillips; Carol Dawson-Rose; Marta Rivero-Mendez; Scholastika Iipinge; Puangtip Chaiphibalsarisdi; Carmen J Portillo; Wei-Ti Chen; Allison R Webel; John Brion; Mallory O Johnson; Joachim Voss; Mary Jane Hamilton; Kathleen M Sullivan; Kenn M Kirksey; Patrice K Nicholas Journal: AIDS Patient Care STDS Date: 2017-05 Impact factor: 5.078
Authors: James H Willig; Andrew O Westfall; Michael Mugavero; Christa R Nevin; Todd Correll; Amit Duggal; William Guyer; Michael S Saag; Timothy Juday Journal: AIDS Res Hum Retroviruses Date: 2012-12-18 Impact factor: 2.205
Authors: Kathleen E Squires; Linda-Gail Bekker; Joseph J Eron; Benjamin Cheng; Juergen K Rockstroh; Farid Marquez; Princy Kumar; Melanie Thompson; Rafael E Campo; Karam Mounzer; Kim M Strohmaier; Chengxing Lu; Anthony Rodgers; Beth E Jackson; Larissa A Wenning; Michael Robertson; Bach-Yen T Nguyen; Peter Sklar Journal: AIDS Res Hum Retroviruses Date: 2013-02-26 Impact factor: 2.205